This month Asia correspondent A Nair looks at why the emerging economies provide so many tempting takeover targets for Big Pharma
Mergers and acquisitions (M&A) activity in the pharmaceutical sector seems to be picking up this year, especially deals involving Indian, Brazilian and Chinese (BRIC) companies. Big Pharma has been eager to penetrate the emerging markets of India and China for some time now and its sights are set firmly on the generic pharmaceutical industry in these countries.
India is set to see plenty of M&A activity this year. According to consulting firm Grant Thornton, the high expectations could be explained by factors such as the impending patent cliff in the US, the increasing attractiveness of India as a low-cost research and development destination and the increasing success of Indian firms in getting abbreviated new drug approvals (ANDA).
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.